VCM
TVRD

Versant Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Versant Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$41 – 1958
2023
Q4 		$41 Hold
2
– – ﹤0.01% 1908
2023
Q3 		$92 Hold
2
– – ﹤0.01% 1920
2023
Q2 		$156 Hold
2
– – ﹤0.01% 2013
2023
Q1 		$270 Hold
2
– – ﹤0.01% 1678
2022
Q4 		$591 Hold
2
– – ﹤0.01% 1410
2022
Q3 		$1K Hold
2
– – ﹤0.01% 1380
2022
Q2 		$1K Buy
+2
New +$702 ﹤0.01% 1387
2022
Q1 		– Hold
0
– – – 1665
2021
Q4 		– Sell
-20
Closed -$10.1K – 1614
2021
Q3 		$11K Buy
20
+14
+233% +$7.02K ﹤0.01% 682
2021
Q2 		$3K Buy
+6
New +$3.8K ﹤0.01% 1084

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Versant Capital Management's TVRD Position: Q1 2024 in Review

Versant Capital Management sold out of Tvardi Therapeutics (TVRD) in Q1 2024, closing a stake of 2 shares — an estimated $41 sold.

Versant Capital Management first reported a position in TVRD in Q2 2021 and held it in 9 quarters. The position peaked at $11K in Q3 2021. 97 funds tracked by Wall St. Rank hold TVRD as of Q1 2024.

  • Versant Capital Management reported no remaining Tvardi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Versant Capital Management sold 2 Tvardi Therapeutics shares in Q1 2024, an estimated $41.
  • Versant Capital Management first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 9 quarters.
  • Versant Capital Management's Tvardi Therapeutics position peaked at $11K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2024.

Based on Versant Capital Management's 13F filing for Q1 2024, filed 3 Apr 2024.